The goal of the Preclinical Hub (PCH)  Program is to stimulate NF drug discovery by funding the development of relevant and translational preclinical tools to support drug screening efforts as part of the Preclinical Hub model. The Preclinical Hub will serve to provide access to NF-focused tools and resources for the purposes of accelerating drug development efforts.

Specifically, the aims of the PCH Program are to support the generation of clinically-relevant in vitro (cell-based) or in vivo (whole animal) model systems for NF. Topics of specific interest to CTF will include in vivo and in vitro models of non-NF2-related SWN, cutaneous neurofibromas as well as genetically modified models of  NF1-related learning and cognitive deficits or pain in schwannomatosis.

See more details